Methionine alone cannot compensate for choline deficiency, and choline cannot bypass impaired SAMe synthesis if methionine is depleted
If irritation continues, apply an over-the-counter itch cream, preferably with hydrocortisone, or discontinue use and contact your provider

Key facts for understanding the device context: Trial structure: Four or more core trials (TRIUMPH-1 through TRIUMPH-4 plus TRIUMPH-Outcomes), enrolling 5,800 or more participants across programs Administration: Subcutaneous injection, once weekly, dose escalation to 12mg maximum TRIUMPH-4 results (December 2025): Participants on 12mg retatrutide lost an average of 28.7% body weight at 68 weeks, versus 2.1% on placebo (Giblin et al., PMID 41090431) Phase 2 comparison: 24.2% body weight loss at 48 weeks on 12mg (Jastreboff et al., NEJM 2023) - a different trial, shorter duration, earlier data TRIUMPH-Outcomes: Active Phase 3 trial (NCT06383390), estimated 10,000 participants, completion February 2029 - investigating cardiovascular outcomes What the Phase 3 Device Disclosure Gap Means Eli Lilly has not disclosed pen device specifications for retatrutide because the drug is not yet approved, and device details are part of the commercial product launch package

This is different from GLP-1s mechanism, which primarily reduces the drive to eat and the reward value of food through hypothalamic and mesolimbic circuits
But it's also a pain in the butt
Step 3: Medication Delivery and Authorization If tirzepatide is prescribed, expect swift prior authorization handling and medication delivery through Klinic